Decane-1,2-diol derivatives as potential antitumor agents for the treatment of glioblastoma.

Authors

Anisha Viswanathan
Anastasia Zhurina
Benedicta Assoah
Aleksi Paakkunainen
Aliyu Musa
Dinesh Kute
Konda Mani Saravanan
Olli Yli-Harja, Molecular Signaling Lab, Computational Systems Biology Research Group, BioMediTech and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland; Institute for Systems Biology, 1441N 34th Street, Seattle, WA 98103-8904, USA
Nuno R Candeias
Meenakshisundaram Kandhavelu

Document Type

Article

Publication Date

10-15-2018

Keywords

Alcohols; Anti-cancer drugs; Glioblastoma

Abstract

Glioblastoma remains the most common and aggressive type of malignant brain tumor among adults thus, considerable attention has been given to discovery of novel anti-tumor drugs for its treatment. This study reports the synthesis of a series of twelve novel decane-1,2-diol derivatives and evaluation of its anti-tumor activity in mammalian glioblastoma cell lines, U87 and LN229. Starting from decane-1,2-diol, several derivatives were prepared using a diversity oriented synthesis approach through which a small library composed of esters, silyl ethers, sulfonates, sulfites, sulfates, ketals, and phosphonates was built. The decane-1,2-diol ditosylated derivative, DBT, found to have higher cytotoxicity than the standard drug cisplatin, has IC

Specialty/Research Institute

Institute for Systems Biology